Aronnax to Determine the Maximum-Tolerated
Dose (MTD) Post Intravenous Injection Followed by a Dose
Range-Finding Phase of Hoth's Orphan Drug HT-KIT
NEW
YORK, Aug. 15, 2024 /PRNewswire/ -- Hoth
Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused
biopharmaceutical company, today announced that it has entered
into a Master Services Agreement with Aronnax, Inc. for its HT-KIT
cancer therapeutic.
HT-KIT research, which was conducted at NC State University
to evaluate the efficacy of HT-KIT in cancerous and non-cancerous
cells, has demonstrated that HT-KIT effectively kills human mast
cells that rely on signaling through the KIT receptor to survive.
The effect of a single dose lasted for about two weeks, while
reduced KIT expression lasted for 7 days. This result also
demonstrated HT-KIT's potential to reduce KIT expression using GIST
cells and kill within 48 and 72 hours along with lower KIT
expression in AML cells over 72 hours.
HT-KIT is an antisense oligonucleotide that targets the
proto-oncogene cKIT being developed for the treatment of mast
cell-derived cancers and anaphylaxis and previously received Orphan
Drug Designation from FDA.
Aronnax will oversee the third-party provider, ITR Laboratories,
conducting intravenous injection using increasing/decreasing doses
for each subsequent group. A timeframe of forty-eight hours will be
allowed between each dose group. This study will provide Hoth key
metrics in both max dose and range finding elements which will help
formulate its proposed clinical trial.
"We continue to make quick progress in moving HT-KIT from the
lab to patients. This further analysis will help us with that
process, finalizing the protocols in our upcoming IND-enabling
study," stated Robb Knie, Chief Executive Officer. "We are
pleased to further engage Aronnax and ITR Laboratories on these key
studies given their reputation for IND-enabling studies."
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company
dedicated to developing innovative, impactful, and ground-breaking
treatments with a goal to improve patient quality of life. We are a
catalyst in early-stage pharmaceutical research and development,
elevating drugs from the bench to pre-clinical and clinical
testing. Utilizing a patient-centric approach, we collaborate and
partner with a team of scientists, clinicians, and key opinion
leaders to seek out and investigate therapeutics that hold immense
potential to create breakthroughs and diversify treatment options.
To learn more, please visit https://ir.hoththerapeutics.com/.
Forward-Looking Statement
This press release includes forward-looking statements based
upon Hoth's current expectations, which may constitute
forward-looking statements for the purposes of the safe harbor
provisions under the Private Securities Litigation Reform Act of
1995 and other federal securities laws, and are subject to
substantial risks, uncertainties, and assumptions. These statements
concern Hoth's business strategies; the timing of regulatory
submissions; the ability to obtain and maintain regulatory approval
of existing product candidates and any other product candidates we
may develop, and the labeling under any approval we may obtain; the
timing and costs of clinical trials, and the timing and costs of
other expenses; market acceptance of our products; the ultimate
impact of the current coronavirus pandemic, or any other health
epidemic, on our business, our clinical trials, our research
programs, healthcare systems, or the global economy as a whole; our
intellectual property; our reliance on third-party organizations;
our competitive position; our industry environment; our anticipated
financial and operating results, including anticipated sources of
revenues; our assumptions regarding the size of the available
market, benefits of our products, product pricing, and timing of
product launches; management's expectation with respect to future
acquisitions; statements regarding our goals, intentions, plans,
and expectations, including the introduction of new products and
markets; and our cash needs and financing plans. There are a number
of factors that could cause actual events to differ materially from
those indicated by such forward-looking statements. You should not
place reliance on these forward-looking statements, which include
words such as "could," "believe," "anticipate," "intend,"
"estimate," "expect," "may," "continue," "predict," "potential,"
"project" or similar terms, variations of such terms, or the
negative of those terms. Although the Company believes that the
expectations reflected in the forward-looking statements are
reasonable, the Company cannot guarantee such outcomes. Hoth may
not realize its expectations, and its beliefs may not prove
correct. Actual results may differ materially from those indicated
by these forward-looking statements as a result of various
important factors, including, without limitation, market conditions
and the factors described in the section titled "Risk Factors" in
Hoth's most recent Annual Report on Form 10-K and Hoth's other
filings made with the U. S. Securities and Exchange Commission. All
such statements speak only as of the date made. Consequently,
forward-looking statements should be regarded solely as Hoth's
current plans, estimates, and beliefs. Investors should not place
undue reliance on forward-looking statements. Hoth cannot guarantee
future results, events, levels of activity, performance, or
achievements. Hoth does not undertake and specifically declines any
obligation to update, republish, or revise any forward-looking
statements to reflect new information, future events, or
circumstances or to reflect the occurrences of unanticipated
events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-and-aronnax-inc-enter-master-services-agreement-for-ht-kit-cancer-therapeutic-302223147.html
SOURCE Hoth Therapeutics, Inc.